Top Industry Leaders in the Asthma COPD Drugs Market
Latest Asthma and COPD Drugs Companies Update:
GlaxoSmithKline (GSK) Presented positive Phase 3 data for their investigational IL-5 inhibitor, BEZP1144, demonstrating significant improvements in lung function and reduction in exacerbations for severe asthma patients.
AstraZeneca Received FDA approval for the first generic version of Symbicort, opening up cost-effective treatment options for patients.
Viatris and Kindeva Drug Delivery Launched Breyna, a budesonide-formoterol combination inhaler for asthma and COPD, targeting patients above six years old.
Novartis Announced expansion of clinical trials for their IL-17/IL-17A inhibitor, QGE003, to include patients with moderate-to-severe COPD.
Roche Collaborated with Lung Foundation Australia to develop and implement a digital platform for self-management of chronic respiratory diseases like asthma and COPD.
List of Asthma and COPD Drugs Key companies in the market
- Teva Pharmaceutical Industries Ltd (Israel)
- GSK plc (UK)
- Merck& Co., Inc (US)
- Hoffmann-La Roche Ltd (Switzerland)
- AstraZeneca (UK)
- Boehringer Ingelheim International GmbH (Germany)
- Sanofi (France)
- Koninklijke Philips N.V. (Netherlands)
- BD (US)
- Sunovion Pharmaceuticals, Inc (US)